Clinical Trial Update: An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice

View source ↗

Summary

This entry reports the completion of an Indian post-marketing study evaluating the safety and effectiveness of Fiasp mealtime insulin in routine clinical practi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• Fiasp (insulin aspart)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | Status: COMPLETED